Unmasking the interplay between mTOR and Nox4: novel insights into the mechanism connecting diabetes and cancer.
AMP-Activated Protein Kinases
/ antagonists & inhibitors
Animals
Antibiotics, Antineoplastic
/ pharmacology
Blood Glucose
Caco-2 Cells
DNA Damage
Diabetes Mellitus, Experimental
Gene Expression Regulation, Neoplastic
/ drug effects
HT29 Cells
Humans
Hypoglycemic Agents
/ pharmacology
Male
Metformin
/ pharmacology
Mice
Mice, Inbred C57BL
Mice, Transgenic
NADPH Oxidase 4
/ genetics
Sirolimus
/ pharmacology
TOR Serine-Threonine Kinases
/ antagonists & inhibitors
Up-Regulation
DNA damage
NADPH oxidases
colorectal cancer
mTORC1
Journal
FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
pubmed:
30
10
2019
medline:
27
6
2020
entrez:
30
10
2019
Statut:
ppublish
Résumé
Cancer was recently annexed to diabetic complications. Furthermore, recent studies suggest that cancer can increase the risk of diabetes. Consequently, diabetes and cancer share many risk factors, but the cellular and molecular pathways correlating diabetes and colon and rectal cancer (CRC) remain far from understood. In this study, we assess the effect of hyperglycemia on cancer cell aggressiveness in human colon epithelial adenocarcinoma cells
Identifiants
pubmed: 31661292
doi: 10.1096/fj.201900396RR
doi:
Substances chimiques
Antibiotics, Antineoplastic
0
Blood Glucose
0
Hypoglycemic Agents
0
Metformin
9100L32L2N
NADPH Oxidase 4
EC 1.6.3.-
NOX4 protein, human
EC 1.6.3.-
Nox4 protein, mouse
EC 1.6.3.-
MTOR protein, human
EC 2.7.1.1
mTOR protein, mouse
EC 2.7.1.1
TOR Serine-Threonine Kinases
EC 2.7.11.1
AMP-Activated Protein Kinases
EC 2.7.11.31
Sirolimus
W36ZG6FT64
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
14051-14066Références
Limburg, P. J., Vierkant, R. A., Fredericksen, Z. S., Leibson, C. L., Rizza, R. A., Gupta, A. K., Ahlquist, D. A., Melton L. J. III, Sellers, T. A., and Cerhan, J. R. (2006) Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective cohort study. Am. J. Gastroenterol. 101, 1872-1879
Oh, S.-W., Kim, Y.-H., Choi, Y. S., Chang, D. K., Son, H. J., Rhee, P.-L., Kim, J. J., Rhee, J. C., Yun, S. H., Lee, W. Y., Chun, H. K., Kim, D. H., and Shim, S. G. (2008) The comparison of the risk factors and clinical manifestations of proximal and distal colorectal cancer. Dis. Colon Rectum 51, 56-61
Ren, X., Zhang, X., Zhang, X., Gu, W., Chen, K., Le, Y., Lai, M., and Zhu, Y. (2009) Type 2 diabetes mellitus associated with increased risk for colorectal cancer: evidence from an international ecological study and population-based risk analysis in China. Public Health 123, 540-544
Elwing, J. E., Gao, F., Davidson, N. O., and Early, D. S. (2006) Type 2 diabetes mellitus: the impact on colorectal adenoma risk in women. Am. J. Gastroenterol. 101, 1866-1871
Yang, Y. X., Hennessy, S., and Lewis, J. D. (2004) Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients. Gastroenterology 127, 1044-1050
Yang, Y.-X., Hennessy, S., and Lewis, J. D. (2005) Type 2 diabetes mellitus and the risk of colorectal cancer. Clin. Gastroenterol. Hepatol. 3, 587-594
Chung, Y. W., Han, D. S., Park, K. H., Eun, C. S., Yoo, K.-S., and Park, C. K. (2008) Insulin therapy and colorectal adenoma risk among patients with Type 2 diabetes mellitus: a case-control study in Korea. Dis. Colon Rectum 51, 593-597
Nagel, J. M., and Göke, B. (2006) [Colorectal carcinoma screening in patients with type 2 diabetes mellitus]. Z. Gastroenterol. 44, 1153-1165
Slattery, M. L., Herrick, J. S., Lundgreen, A., Fitzpatrick, F. A., Curtin, K., and Wolff, R. K. (2010) Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1. Carcinogenesis 31, 1604-1611
Mochizuki, T., Furuta, S., Mitsushita, J., Shang, W. H., Ito, M., Yokoo, Y., Yamaura, M., Ishizone, S., Nakayama, J., Konagai, A., Hirose, K., Kiyosawa, K., and Kamata, T. (2006) Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC-1 cells. Oncogene 25, 3699-3707
Wullschleger, S., Loewith, R., and Hall, M. N. (2006) TOR signaling in growth and metabolism. Cell 124, 471-484
Viollet, B., Andreelli, F. J⊘rgensen, S. B., Perrin, C., Flamez, D., Mu, J., Wojtaszewski, J. F., Schuit, F. C., Birnbaum, M., Richter, E., Burcelin, R., and Vaulont, S. (2003) Physiological role of AMP-activated protein kinase (AMPK): insights from knockout mouse models. Biochem. Soc. Trans. 31, 216-219
Shaw, R. J., Kosmatka, M., Bardeesy, N., Hurley, R. L., Witters, L. A., DePinho, R. A., and Cantley, L. C. (2004) The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. USA 101, 3329-3335
Singh, S., Earle, C. C., Bae, S. J., Fischer, H. D., Yun, L., Austin, P. C., Rochon, P. A., Anderson, G. M., and Lipscombe, L. (2016) Incidence of diabetes in colorectal cancer survivors. J. Natl. Cancer Inst. 108, djv402
Hwangbo, Y., Kang, D., Kang, M., Kim, S., Lee, E. K., Kim, Y. A., Chang, Y. J., Choi, K. S., Jung, S. Y., Woo, S. M., Ahn, J. S., Sim, S. H., Hong, Y. S., Pastor-Barriuso, R., Guallar, E., Lee, E. S., Kong, S. Y., and Cho, J. (2018) Incidence of diabetes after cancer development: a Korean national cohort study. JAMA Oncol. 4, 1099-1105
Shin, D. W., Ahn, E., Kim, H., Park, S., Kim, Y. A., and Yun, Y. H. (2010) Non-cancer mortality among long-term survivors of adult cancer in Korea: national cancer registry study. Cancer Causes Control 21, 919-929
Holmes, H. M., Nguyen, H. T., Nayak, P., Oh, J. H., Escalante, C. P., and Elting, L. S. (2014) Chronic conditions and health status in older cancer survivors. Eur. J. Intern. Med. 25, 374-378
Vigneri, P., Frasca, F., Sciacca, L., Pandini, G., and Vigneri, R. (2009) Diabetes and cancer. Endocr. Relat. Cancer 16, 1103-1123
Tsilidis, K K, Kasimis, J. C., Lopez, D. S., Ntzani, E. E., and loannidis, J. P. A. (2015) Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. BMJ 350, g7607
Lipscombe, L. L., Chan, W. W., Yun, L., Austin, P. C., Anderson, G. M., and Rochon, P. A. (2013) Incidence of diabetes among postmenopausal breast cancer survivors. Diabetologia 56, 476-483
De Bruijn, K. M. J., and van Eijck, C. H. J. (2015) New-onset diabetes after distal pancreatectomy: a systematic review. Ann. Surg. 261, 854-861
Eid, S., Boutary, S., Braych, K., Sabra, R., Massaad, C., Hamdy, A., Rashid, A., Moodad, S., Block, K., Gorin, Y., Abboud, H. E., and Eid, A. A. (2016) mTORC2 signaling regulates Nox4-induced podocyte depletion in diabetes. Antioxid. Redox Signal. 25, 703-719
Eid, A. A., Ford, B. M., Bhandary, B., de Cassia Cavaglieri, R., Block, K., Barnes, J. L., Gorin, Y., Choudhury, G. G., and Abboud, H. E. (2013) Mammalian target of rapamycin regulates Nox4-mediated podocyte depletion in diabetic renal injury. Diabetes 62, 2935-2947
Eid, A. A., Ford, B. M., Block, K., Kasinath, B. S., Gorin, Y., Ghosh-Choudhury, G., Barnes, J. L., and Abboud, H. E. (2010) AMP-activated protein kinase (AMPK) negatively regulates NOX4-dependent activation of p53 and epithelial cell apoptosis in diabetes. J. Biol. Chem. 285, 37503-37512
Eid, A. A., Gorin, Y., Fagg, B. M., Maalouf, R., Barnes, J. L., Block, K., and Abboud, H. E. (2009) Mechanisms of podocyte injury in diabetes: role of cytochrome P450 and NADPH oxidases. Diabetes 58, 1201-1211
Fitzgerald, J. P., Nayak, B., Shanmugasundaram, K., Friedrichs, W., Sudarshan, S., Eid, A. A., DeNapoli, T., Parekh, D. J., Gorin, Y., and Block, K. (2012) Nox4 mediates renal cell carcinoma cell invasion through hypoxia-induced interleukin 6- and 8- production. PLoS One 7, e30712
Brieger, K., Schiavone, S., Miller, F. J., Jr., and Krause, K.-H. (2012) Reactive oxygen species: from health to disease. Swiss Med. Wkly. 142, w13659
Giouleme, O., Diamantidis, M. D., and Katsaros, M. G. (2011) Is diabetes a causal agent for colorectal cancer? Pathophysiological and molecular mechanisms. World J. Gastroenterol. 17, 444-448
Storz, P. (2005) Reactive oxygen species in tumor progression. Front. Biosci. 10, 1881-1896
Szatrowski, T. P., and Nathan, C. F. (1991) Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res. 51, 794-798
Inoki, K., and Guan, K.-L. (2009) Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment. Hum. Mol. Genet. 18 (R1), R94-R100
Nozawa, H., Watanabe, T., and Nagawa, H. (2007) Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer. Cancer Lett. 251, 105-113
Sarbassov, D. D., Guertin, D. A., Ali, S. M., and Sabatini, D. M. (2005) Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101
Zendehdel, K., Nyren, O., Ostenson, C.-G., Adami, H.-O., Ekbom, A., and Ye, W. (2003) Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J. Natl. Cancer Inst. 95, 1797-1800
Loft, S., H⊘gh Danielsen, P., Mikkelsen, L., Risom, L., Forchhammer, L., and M⊘ller, P. (2008) Biomarkers of oxidative damage to DNA and repair. Biochem. Soc. Trans. 36, 1071-1076
Dziaman, T., Banaszkiewicz, Z., Roszkowski, K., Gackowski, D., Wisniewska, E., Rozalski, R., Foksinski, M., Siomek, A., Speina, E., Winczura, A., Marszalek, A., Tudek, B., and Olinski, R. (2014) 8-Oxo-7,8-dihydroguanine and uric acid as efficient predictors of survival in colon cancer patients. Int. J. Cancer 134, 376-383
Roszkowski, K., and Olinski, R. S. (2012) Urinary 8-oxoguanine as a predictor of survival in patients undergoing radiotherapy. Cancer Epidemiol. Biomarkers Prev. 21, 629-634
Mitra, S., Boldogh, I., Izumi, T., and Hazra, T. K. (2001) Complexities of the DNA base excision repair pathway for repair of oxidative DNA damage. Environ. Mol. Mutagen. 38, 180-190
Hung, R. J., Hall, J., Brennan, P., and Boffetta, P. (2005) Genetic polymorphisms in the base excision repair pathway and cancer risk: a HuGE review. Am. J. Epidemiol. 162, 925-942
Srivastava, A., Srivastava, K., Pandey, S. N., Choudhuri, G., and Mittal, B. (2009) Single-nucleotide polymorphisms of DNA repair genes OGG1 and XRCC1: association with gallbladder cancer in North Indian population. Ann. Surg. Oncol. 16, 1695-1703
Zhang, J., Zhou, J., Zhang, P., Wang, W., Tao, S., and Wang, M. (2013) A meta-analysis of the association between the hOGG1 Ser326Cys polymorphism and the risk of esophageal squamous cell carcinoma. PLoS One 8, e65742
Duan, W.-X., Hua, R.-X., Yi, W., Shen, L.-J., Jin, Z.-X., Zhao, Y.-H., Yi, D. H., Chen, W. S., and Yu, S. Q. (2012) The association between OGG1 Ser326Cys polymorphism and lung cancer susceptibility: a meta-analysis of 27 studies. PLoS One 7, e35970
Das, S., Nath, S., Bhowmik, A., Ghosh, S. K., and Choudhury, Y. (2016) Association between OGG1 Ser326Cys polymorphism and risk of upper aero-digestive tract and gastrointestinal cancers: a meta-analysis. Springerplus 5, 227
Szablewski, L. (2014) Diabetes mellitus: influences on cancer risk. Diabetes Metab. Res. Rev. 30, 543-553
Hawley, S. A., Davison, M., Woods, A., Davies, S. P., Beri, R. K., Carling, D., and Hardie, D. G. (1996) Characterization of the AMP-activated protein kinase kinase from rat liver and identification of threonine 172 as the major site at which it phosphorylates AMP-activated protein kinase. J. Biol. Chem. 271, 27879-27887
Motoshima, H., Goldstein, B. J., Igata, M., and Araki, E. (2006) AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J. Physiol. 574, 63-71
Cheng, S. W. Y., Fryer, L. G. D., Carling, D., and Shepherd, P. R. (2004) Thr2446 is a novel mammalian target of rapamycin (mTOR) phosphorylation site regulated by nutrient status. J. Biol. Chem. 279, 15719-15722
Hardie, D. G., Carling, D., and Carlson, M. (1998) The AMP-activated/SNF1 protein kinase subfamily: metabolic sensors of the eukaryotic cell? Annu. Rev. Biochem. 67, 821-855
Riboulet-Chavey, A., Diraison, F., Siew, L. K., Wong, F. S., and Rutter, G. A. (2008) Inhibition of AMP-activated protein kinase protects pancreatic beta-cells from cytokine-mediated apoptosis and CD8+ T-cell-induced cytotoxicity. Diabetes 57, 415-423
Yellen, P., Saqcena, M., Salloum, D., Feng, J., Preda, A., Xu, L., Rodrik-Outmezguine, V., and Foster, D. A. (2011) High-dose rapamycin induces apoptosis in human cancer cells by dissociating mTOR complex 1 and suppressing phosphorylation of 4E-BP1. Cell Cycle 10, 3948-3956
Moser, A. R., Luongo, C., Gould, K. A., McNeley, M. K., Shoemaker, A. R., and Dove, W. F. (1995) ApcMin: a mouse model for intestinal and mammary tumorigenesis. Eur. J. Cancer 31A, 1061-1064
Furman, B. L. (2015) Streptozotocin-induced diabetic models in mice and rats. Curr. Protocols Pharmacol. 70, 1-20
Kim, J., Yang, G., Kim, Y., Kim, J., and Ha, J. (2016) AMPK activators: mechanisms of action and physiological activities. Exp. Mol. Med. 48, e224
Eid, A. A., Lee, D.-Y., Roman, L. J., Khazim, K., and Gorin, Y. (2013) Sestrin 2 and AMPK connect hyperglycemia to Nox4-dependent endothelial nitric oxide synthase uncoupling and matrix protein expression. Mol. Cell. Biol. 33, 3439-3460
Rodriguez, L. G., Wu, X., and Guan, J.-L. (2005) Wound-healing assay. In Cell Migration, pp. 23-29, Springer, Berlin, Germany
Block, K., and Gorin, Y. (2012) Aiding and abetting roles of NOX oxidases in cellular transformation. Nat. Rev. Cancer 12, 627-637
Saito, N., Nishimura, H., and Kameoka, S. (2008) Clinical significance of fibronectin expression in colorectal cancer. Mol. Med. Rep. 1, 77-81
Meng, S., Cao, J., He, Q., Xiong, L., Chang, E., Radovick, S., Wondisford, F. E., and He, L. (2015) Metformin activates AMP-activated protein kinase by promoting formation of the αβγ heterotrimeric complex. J. Biol. Chem. 290, 3793-3802
Guo, W., and Frenette, P. S. (2014) Alternative CD44 splicing in intestinal stem cells and tumorigenesis. Oncogene 33, 537-538
Xia, P., and Xu, X.-Y. (2016) Prognostic significance of CD44 in human colon cancer and gastric cancer: evidence from bioinformatic analyses. Oncotarget 7, 45538-45546
Fuishita, T., Kojima, Y., Kajino-Sakamoto, R., Taketo, M. M., and Aoki, M. (2017) Tumor microenvironment confers mTOR inhibitor resistance in invasive intestinal adenocarcinoma. Oncogene 36, 6480-6489
Tomimoto, A., Endo, H., Sugiyama, M., Fujisawa, T., Hosono, K., Takahashi, H., Nakqima, N., Nagashima, Y., Wada, K., Nakagama, H., and Nakajima, A. (2008) Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci. 99, 2136-2141
Cheung, A. F., Carter, A. M., Kostova, K. K., Woodruff, J. F., Crowley, D., Bronson, R. T., Haigis, K. M., and Jacks, T. (2010) Complete deletion of Apc results in severe polyposis in mice. Oncogene 29, 1857-1864
Suchanek, S., Grega, T., Ngo, O., Vojtechova, G., Majek, O., Minarikova, P., Brogyuk, N., Bunganic, B., Seifert, B., Dusek, L., and Zavoral, M. (2016) How significant is the association between metabolic syndrome and prevalence of colorectal neoplasia? World J. Gastroenterol. 22, 8103-8111
Vasconcelos-Dos-Santos, A., Loponte, H. F., Mantuano, N. R., Oliveira, I. A., de Paula, I. F., Teixeira, L. K., de-Freitas, Junior, J. C., Gondim, K. C., Heise, N., Mohana-Borges, R., Morgado-Díaz, J. A., Dias, W. B., and Todeschini, A. R. (2017) Hyperglycemia exacerbates colon cancer malignancy through hexosamine biosynthetic pathway. Oncogenesis 6, e306
Siddiqui, A. A., Spechler, S. J., Huerta, S., Dredar, S., Little, B. B., and Cryer, B. (2008) Elevated HbA1c is an independent predictor of aggressive clinical behavior in patients with colorectal cancer: a case-control study. Dig. Dis. Sci. 53, 2486-2494
Pan, H.-Z., Zhang, H., Chang, D., Li, H., and Sui, H. (2008) The change of oxidative stress products in diabetes mellitus and diabetic retinopathy. Br. J. Ophthalmol. 92, 548-551
Al-Shabrawey, M., Bartoli, M., El-Remessy, A. B., Ma, G., Matragoon, S., Lemtalsi, T., Caldwell, R. W., and Caldwell, R. B. (2008) Role of NADPH oxidase and Stat3 in statin-mediated protection against diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 49, 3231-3238
Rojas, A., Mercadal, E., Figueroa, H., and Morales, M. A. (2008) Advanced Glycation and ROS: a link between diabetes and heart failure. Curr. Vasc. Pharmacol. 6, 44-51
Dizdaroglu, M., and Jaruga, P. (2012) Mechanisms of free radical-induced damage to DNA. Free Radic. Res. 46, 382-419
Cadet, J., and Wagner, J. R. (2014) Oxidatively generated base damage to cellular DNA by hydroxyl radical and one-electron oxidants: similarities and differences. Arch. Biochem. Biophys. 557, 47-54
Ogrunc, M., Di Micco, R., Liontos, M., Bombardelli, L., Mione, M., Fumagalli, M., Gorgoulis, V. G., and d'Adda di Fagagna, F. (2014) Oncogene-induced reactive oxygen species fuel hyperproliferation and DNA damage response activation. Cell Death Differ. 21, 998-1012
Filla, L. A., and Edwards, J. L. (2016) Metabolomics in diabetic complications. Mol. Biosyst. 12, 1090-1105
Chew, S. H., and Toyokuni, S. (2015) Malignant mesothelioma as an oxidative stress-induced cancer: an update. Free Radic. Biol. Med. 86, 166-178
Rodriguez, Y., Hinz, J. M., and Smerdon, M. J. (2015) Accessing DNA damage in chromatin: preparing the chromatin landscape for base excision repair. DNA Repair (Amst.) 32, 113-119
Vaquero, E. C., Edderkaoui, M., Pandol, S. J., Gukovsky, I., and Gukovskaya, A. S. (2004) Reactive oxygen species produced by NAD(P)H oxidase inhibit apoptosis in pancreatic cancer cells. J. Biol. Chem. 279, 34643-34654
Maalouf, R. M., Eid, A. A., Gorin, Y. C., Block, K., Escobar, G. P., Bailey, S., and Abboud, H. E. (2012) Nox4-derived reactive oxygen species mediate cardiomyocyte injury in early type 1 diabetes. Am. J. Physiol. Cell Physiol. 302, C597-C604
Thallas-Bonke, V., Jandeleit-Dahm, K. A. M., and Cooper, M. E. (2015) Nox-4 and progressive kidney disease. Curr. Opin. Nephrol. Hypertens. 24, 74-80
Thallas-Bonke, V., Jha, J. C., Gray, S. P., Barit, D., Haller, H., Schmidt, H. H., Coughlan, M. T., Cooper, M. E., Forbes, J. M., and Jandeleit-Dahm, K. A. (2014) Nox-4 deletion reduces oxidative stress and injury by PKC-α-associated mechanisms in diabetic nephropathy. Physiol. Rep. 2, e12192
Sedeek, M., Montezano, A. C., Hebert, R. L., Gray, S. P., Di Marco, E., Jha, J. C., Cooper, M. E., Jandeleit-Dahm, K., Schiffrin, E. L., Wilkinson-Berka, J. L., and Touyz, R. M. (2012) Oxidative stress, Nox isoforms and complications of diabetes-potential targets for novel therapies. J. Cardiovasc. Transí. Ríes. 5, 509-518
Bauer, T. M., Patel, M. R., and Infante, J. R. (2015) Targeting PI3 kinase in cancer. Pharmacol. Ther. 146, 53-60
Zhang, Z.-Y., Dodd, G. T., and Tiganis, T. (2015) Protein tyrosine phosphatases in hypothalamic insulin and leptin signaling. Trends Pharmacol. Sci. 36, 661-674
Jeon, S.-M., and Hay, N. (2015) The double-edged sword of AMPK signaling in cancer and its therapeutic implications. Arch. Pharm. Res. 38, 346-357
Arbiser, J. L., Brat, D., Hunter, S., D'Armiento, J., Henske, E. P., Arbiser, Z. K., Bai, X., Goldberg, G., Cohen, C., and Weiss, S. W. (2002) Tuberous sclerosis-associated lesions of the kidney, brain, and skin are angiogenic neoplasms. J. Am. Acad. Dermatol. 46, 376-380
Park, I. J., Hwang, J. T., Kim, Y. M., Ha, J., and Park, O. J. (2006) Differential modulation of AMPK signaling pathways by low or high levels of exogenous reactive oxygen species in colon cancer cells. Ann. N. Y. Acad. Sci. 1091, 102-109
Yue, W., Yang, C. S., DiPaola, R. S., and Tan, X.-L. (2014) Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. Cancer Prev. Res. (Phila.) 7, 388-397
Rattan, R., Giri, S., Singh, A. K., and Singh, I. (2005) 5-Aminoimidazole-4-carboxamide-1-β-D-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J. Biol. Chem. 280, 39582-39593
Xiang, X., Saha, A K, Wen, R., Ruderman, N. B., and Luo, Z. (2004) AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem. Biophys. Res. Commun. 321, 161-167
Imamura, K., Ogura, T., Kishimoto, A., Kaminishi, M., and Esumi, H. (2001) Cell cycle regulation via p53 phosphorylation by a 5′-AMP activated protein kinase activator, 5-aminoimidazole- 4-carboxamide-1-β-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem. Biophys. Res. Commun. 287, 562-567
Lloberas, N., Cruzado, J. M., Franquesa, M., Herrero-Fresneda, I., Torras, J., Alperovich, G., Rama, I., Vidal, A., and Grinyó, J. M. (2006) Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats. J. Am. Soc. Nephrol. 17, 1395-1404
Yang, Q., and Guan, K.-L. (2007) Expanding mTOR signaling. Cell Res. 17, 666-681
Sugiyama, M., Takahashi, H., Hosono, K., Endo, H., Kato, S., Yoneda, K., Nozaki, Y., Fujita, K., Yoneda, M., Wada, K., Nakagama, H., and Nakajima, A. (2009) Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int. J. Oncol. 34, 339-344
Faubert, B., Vincent, E. E., Poffenberger, M. C., and Jones, R. G. (2015) The AMP-activated protein kinase (AMPK) and cancer: many faces of a metabolic regulator. Cancer Lett. 356 (2 Pt A), 165-170